Download PDF
Pneumologie 2014; 68(08): 542-546
DOI: 10.1055/s-0034-1377332
Review
© Georg Thieme Verlag KG Stuttgart · New York

Assessment of the Effect of Pharmacotherapy in Common Cold/Acute Bronchitis – the Bronchitis Severity Scale (BSS)

Beurteilung der Wirksamkeit von Pharmakotherapie bei Erkältungen/akuter Bronchitis: Bronchitis Severity Scale (BSS)
P. Kardos
1   Group Practice and Centre for Pneumology, Allergy and Sleep Medicine at Red Cross Maingau Hospital, Frankfurt am Main
,
S. Lehrl
2   Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen
,
W. Kamin
3   Pediatric Clinic, Evangelic Hospital Hamm GmbH, Hamm
,
H. Matthys
4   Medical Director emeritus, Department of Pneumology, University Hospital Freiburg
› Author Affiliations
Further Information

Publication History

received10 April 2014

accepted after revision30 April 2014

Publication Date:
08 July 2014 (online)

Also available at
   Permissions and Reprints

Abstract

Background: Acute bronchitis (AB) is a highly contagious infection of the airways, presenting mostly in connection with common cold (CC). There is a high variance in duration and course of symptoms which, sooner or later, also may disappear spontaneously and change during the course of the disease. Therefore, assessment of treatment outcome is difficult.

Methods: Composite outcome measures are commonly used to examine the effects of pharmacotherapy in complex diseases. We discuss the features of the Bronchitis Severity Scale (BSS) on the basis of the available literature.

Results: For the BSS the five most important symptoms of AB are rated by the patient and the physician. Since its introduction in 1996, the BSS has been used in many clinical trials evaluating treatment effects of AB. Its score correlates well with clinical findings. As thorough validation analyses revealed, this applies even more to the BSS subscales “cough domain” and “sputum domain”.

Conclusion: The validated BSS appears to be a reliable tool to assess therapeutic effects in CC/AB. The BSS and its subscales are recommended as outcome measures for future drug trials in CC/AB, but also help physicians to focus their consultation in patients with CC/AB.

Zusammenfassung

Hintergrund: Akute Bronchitis (AB) ist eine Entzündung der Atemwege. Sie tritt meist im Rahmen eines Erkältungsinfektes auf (engl. common cold; CC). Die klinische Symptomatik ist in Dauer und Verlauf äußerst variabel, früher oder später spontan abklingend und kann sich im Krankheitsverlauf ändern, was die Beurteilung der Wirksamkeit von Therapiemaßnahmen erschwert.

Methode: Zur Einschätzung von Behandlungsmaßnahmen bei komplexen Krankheiten werden oft zusammengesetzte Ratingskalen eingesetzt. Wir stellen die Bronchitis Severity Scale (BSS) vor und diskutieren sie anhand vorhandener Literatur.

Ergebnisse: Für die BSS werden die 5 wichtigsten Symptome bei AB von Patient und Arzt eingeschätzt. Seit ihrer Einführung 1996 wurde die BSS in vielen klinischen Studien zur Einschätzung von Therapieeffekten bei AB genutzt. Ihre Resultate stimmten stets gut mit der klinischen Situation überein. Die Validierungsanalyse zeigte, dass die BSS-Unterskalen „Hustendomäne“ und „Sputumdomäne“ die klinischen Gegebenheiten noch genauer widerspiegeln.

Schlussfolgerungen: Die validierte BSS und ihre Unterskalen eignen sich zur Einschätzung von Therapieeffekten bei CC/AB. Sie werden als Zielparameter für klinische Studien empfohlen und erleichtern auch Ärzten die Diagnose.

 

  • References

  • 1 Hueston WJ, Mainous 3rd AG, Dacus EN et al. Does acute bronchitis really exist? A reconceptualization of acute viral respiratory infections. J Fam Pract 2000; 49: 401-406
    PubMedGoogle Scholar
  • 2 Allen LV. Colds & cough. Int J Pharm Compd 2012; 16: 480-483
    PubMedGoogle Scholar
  • 3 Singh M, Singh M. Heated, humidified air for the common cold. Cochrane Database Syst Rev 2013; 6 CD001728
    PubMedGoogle Scholar
  • 4 Wenzel RP, Fowler 3rd AA. Clinical practice. Acute bronchitis. N Engl J Med 2006; 355: 2125-2130
    CrossrefPubMedGoogle Scholar
  • 5 Gulliford MC, van Staa T, McDermott L et al. Cluster randomised trial in the General Practice Research Database: 1. Electronic decision support to reduce antibiotic prescribing in primary care (eCRT study). Trials 2011; 12: 115
    CrossrefPubMedGoogle Scholar
  • 6 Butler CC, Hood K, Verheij T et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ 2009; 338: b2242
    CrossrefPubMedGoogle Scholar
  • 7 Llor C, Moragas A, Bayona C et al. Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial. BMJ 2013; 347: f5762
    CrossrefPubMedGoogle Scholar
  • 8 Smith SM, Fahey T, Smucny J et al. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2014; 3 CD000245
    PubMedGoogle Scholar
  • 9 Lemiengre MB, van Driel ML, Merenstein D et al. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. Cochrane Database Syst Rev 2012; 10 CD006089
    PubMedGoogle Scholar
  • 10 McCallum GB, Morris PS, Chang AB. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. Cochrane Database Syst Rev 2012; 12 CD009834
    PubMedGoogle Scholar
  • 11 Birring SS, Fleming T, Matos S et al. The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 2008; 31: 1013-1018
    CrossrefPubMedGoogle Scholar
  • 12 Matos S, Birring SS, Pavord ID et al. An automated system for 24-h monitoring of cough frequency: the leicester cough monitor. IEEE Trans Biomed Eng 2007; 54: 1472-1479
    CrossrefPubMedGoogle Scholar
  • 13 Lee KK, Matos S, Evans DH et al. A longitudinal assessment of acute cough. Am J Respir Crit Care Med 2013; 187: 991-997
    CrossrefPubMedGoogle Scholar
  • 14 Thompson M, Vodicka TA, Blair PS et al. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ 2013; 347: f7027
    CrossrefPubMedGoogle Scholar
  • 15 Hobbs KF, Cohen MD. Rheumatoid arthritis disease measurement: a new old idea. Rheumatology (Oxford) 2012; 51 (Suppl. 06) vi21-27
    PubMedGoogle Scholar
  • 16 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
    CrossrefPubMedGoogle Scholar
  • 17 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
    CrossrefPubMedGoogle Scholar
  • 18 Guskiewicz KM, Register-Mihalik J, McCrory P et al. Evidence-based approach to revising the SCAT2: introducing the SCAT3. Br J Sports Med 2013; 47: 289-293
    CrossrefPubMedGoogle Scholar
  • 19 Albrecht H, Vernon M, Solomon G. Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms. Respir Res 2012; 13: 118
    CrossrefPubMedGoogle Scholar
  • 20 Mwachari C, Nduba V, Nguti R et al. Validation of a new clinical scoring system for acute bronchitis. Int J Tuberc Lung Dis 2007; 11: 1253-1259
    PubMedGoogle Scholar
  • 21 Nduba VN, Mwachari CW, Magaret AS et al. Placebo found equivalent to amoxicillin for treatment of acute bronchitis in Nairobi, Kenya: a triple blind, randomised, equivalence trial. Thorax 2008; 63: 999-1005
    CrossrefPubMedGoogle Scholar
  • 22 Dome L, Schuster R. Umckaloabo – eine phytotherapeutische Alternative bei akuter Bronchitis im Kindesalter?. Ärztezeitschrift für Naturheilverfahren 1996; 37: 216-222
    PubMedGoogle Scholar
  • 23 Holmes WF, Macfarlane JT, Macfarlane RM et al. Symptoms, signs, and prescribing for acute lower respiratory tract illness. Br J Gen Pract 2001; 51: 177-181
    PubMedGoogle Scholar
  • 24 Kamin W, Ilyenko LI, Malek FA et al. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. Pediatr Int 2012; 54: 219-226
    CrossrefPubMedGoogle Scholar
  • 25 Kamin W, Maydannik V, Malek FA et al. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis – a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int J Clin Pharmacol Ther 2010; 48: 184-191
    CrossrefPubMedGoogle Scholar
  • 26 Kamin W, Maydannik VG, Malek FA et al. Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis. Acta Paediatr 2010; 99: 537-543
    CrossrefPubMedGoogle Scholar
  • 27 Matthys H, Funk P. EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial. Planta Med 2008; 74: 686-692
    Google Scholar
  • 28 Matthys H, Heger M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study. Curr Med Res Opin 2007; 23: 323-331
    CrossrefPubMedGoogle Scholar
  • 29 Matthys H, Heger M. EPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitis. Phytomedicine 2007; 14 (Suppl. 06) 65-68
    PubMedGoogle Scholar
  • 30 Matthys H, Kamin W, Funk P et al. Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children. Phytomedicine 2007; 14 (Suppl. 06) 69-73
    CrossrefPubMedGoogle Scholar
  • 31 Matthys H, Lizogub VG, Malek FA et al. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr Med Res Opin 2010; 26: 1413-1422
    CrossrefPubMedGoogle Scholar
  • 32 Matthys H, Eisebitt R, Seith B et al. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial. Phytomedicine 2003; 10 (Suppl. 04) 7-17
    Google Scholar
  • 33 Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial. Explore (NY) 2005; 1: 437-445
    CrossrefPubMedGoogle Scholar
  • 34 Haidvogl M, Heger M. Treatment effect and safety of EPs 7630-solution in acute bronchitis in childhood: report of a multicentre observational study. Phytomedicine 2007; 14 (Suppl. 06) 60-64
    CrossrefPubMedGoogle Scholar
  • 35 Cwientzek U, Ottillinger B, Arenberger P. Acute bronchitis therapy with ivy leaves extracts in a two-arm study. A double-blind, randomised study vs. an other ivy leaves extract. Phytomedicine 2011; 18: 1105-1109
    CrossrefPubMedGoogle Scholar
  • 36 Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of a fixed combination of thyme and primrose root in patients with acute bronchitis. A double-blind, randomized, placebo-controlled clinical trial. Arzneimittelforschung 2005; 55: 669-676
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Gruenwald J, Graubaum HJ, Busch R. Evaluation of the non-inferiority of a fixed combination of thyme fluid- and primrose root extract in comparison to a fixed combination of thyme fluid extract and primrose root tincture in patients with acute bronchitis. A single-blind, randomized, bi-centric clinical trial. Arzneimittelforschung 2006; 56: 574-581
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Kemmerich B. Evaluation of efficacy and tolerability of a fixed combination of dry extracts of thyme herb and primrose root in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled multicentre clinical trial. Arzneimittelforschung 2007; 57: 607-615
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Gillissen A, Wittig T, Ehmen M et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trial on the efficacy and tolerability of GeloMyrtol(R) forte in acute bronchitis. Drug Res (Stuttg) 2013; 63: 19-27
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Kemmerich B, Eberhardt R, Stammer H. Efficacy and tolerability of a fluid extract combination of thyme herb and ivy leaves and matched placebo in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled clinical trial. Arzneimittelforschung 2006; 56: 652-660
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Marzian O. Treatment of acute bronchitis in children and adolescents. Non-interventional postmarketing surveillance study confirms the benefit and safety of a syrup made of extracts from thyme and ivy leaves [Article in German]. MMW Fortschritte der Medizin 2007; 149 (Suppl. 27) 69-74
    PubMedGoogle Scholar
  • 42 Steinsbekk A, Biolchini J, Heger M et al. Data Collection in Homeopathic Practice - A Proposal for an International Standard. 1999: 1-24 Available at: http://wwwhomeopathyeuropeorg/publications/guidelines/data-collection/datacollhompracpdf [last accessed 03-02-2014]
    PubMedGoogle Scholar
  • 43 Lehrl S. Report on the validity of the Bronchitis Severity Scale (BSS) – a scale for acute bronchitis. Internal Report for Dr Willmar Schwabe GmbH & Co KG. Karlsruhe: 2012: 1-78
    Google Scholar
  • 44 Moosbrugger H, Kelava A. Testtheorie und Fragebogenkonstruktion. 2. ed. Berlin: Springer; 2007
    Google Scholar
  • 45 European Medicines Agency. Committee on Herbal Medicinal Products (HMPC) meeting report on Community herbal monographs, guidelines and other activities. EMA/HMPC/301544/2013
    PubMedGoogle Scholar
  • 46 Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. Current medical research and opinion 2013; 29: 1383-1390
    CrossrefPubMedGoogle Scholar